4-[[1[[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]piperidin-3-yl]methyl]morpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[[1[[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]piperidin-3-yl]methyl]morpholine
• 英文别名: 4-[[1-[[3-[4-(Trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]piperidin-3-yl]methyl]morpholine
• 化学式: C₂₀H₂₅F₃N₄O₂
• 分子量: 410.439
• InChiKey: VFQGZIAZHIRPPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  54.6
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  4-[[1[[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]piperidin-3-yl]methyl]morpholine 在 硫酸 作用下， 以 乙醚 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  [EN] SOLID FORMULATION OF A 1,2,4-OXADIAZOLE DERIVATIVE
  [FR] FORMULATION SOLIDE D'UN DÉRIVÉ DE 1,2,4-OXADIAZOLE

  摘要：

  The present invention relates to a solid formulation comprising: - at least one 1,2,4-oxadiazole derivative of formula (I): wherein R1, R2, R3, R4 and R5 are each independently selected from hydrogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3alkoxy and C1-C3 thioalkyl; and - citric acid and/or saccharin, wherein the molar ratio in the solid formulation between the total amount of citric acid and/or saccharin and the amount of the 1,2,4-oxadiazole derivative(s) ranges from about 2 to about 20. The present invention also relates to process for manufacturing a solid composition according to the invention and to a method for increasing the physical stability of a 1,2,4-oxadiazole derivative of formula (I).

  公开号：

  WO2021009355A1

文献信息

• 1,2,4-OXADIAZOLE DERIVATIVES AS DRUGS MODULATING THE GLP-1 PEPTIDE RECEPTOR
  申请人：Viviabiotech, S.L.

  公开号：EP2668951B1

  公开（公告）日：2016-10-12
• US9050347B2
  申请人：——

  公开号：US9050347B2

  公开（公告）日：2015-06-09